What are analysts' ratings for APLS?
Equity research analysts covering Apellis Pharmaceuticals, Inc. (APLS) maintain a favorable consensus rating, leaning predominantly toward strong buy and buy recommendations from major healthcare investment firms. These optimistic ratings are driven by strong clinical and commercial adoption metrics for its flagship complement-inhibitor therapies targeting geographic atrophy and rare retinal diseases. Institutional researchers highlight that despite initial market launch hurdles and regulatory review expenses, the company's expanding market penetration, robust intellectual property portfolio, and ongoing label expansion clinical trials support a highly positive long-term outlook.
Related FAQs
Treatments developed and commercialized by Apellis Pharmaceuticals, such as specialized therapies for rare diseases, are generally subject to varying levels of coverage and prior authorization requirements by commercial health insurance providers and...
Cedric Francois, holding the position of President and Chief Executive Officer at Apellis Pharmaceuticals, receives an extensive annual remuneration package valued at approximately $10.95 million.
Appili Therapeutics anticipates a progressive future as a specialty biopharmaceutical enterprise focused on developing anti-infective drug candidates addressing critical unmet medical needs in global public health.
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals (ticker APLS) attracts attention from biotechnology and healthcare equity investors following regulatory approvals and commercial launches of specialized therapies targeting rare retinal diseases.
Apellis Pharmaceuticals has reported a trailing twelve months revenue of approximately $1.
In 2007, prior to its corporate name change from Research In Motion (RIM) and before the widespread market disruption caused by modern smartphones, BlackBerry stock experienced an explosive multi-year bull run.
Yes, Bitdeer Technologies Group announced that it had sold its entire Bitcoin treasury, including reserves and weekly production, bringing its Bitcoin balance to zero as of February 20, 2026.
The historical evolution of equity stocks and joint-stock companies began during the era of early European maritime exploration and mercantilism in the 17th century, most notably marked by the establishment of chartered trading enterprises like the D...
Aperam S.A. employs more than 13,000 professionals globally across its advanced stainless steel, specialty alloys, recycling, and renewable energy operations.
Employee reviews, workplace culture evaluations, and corporate feedback platforms indicate that Apellis Pharmaceuticals is generally regarded as a rewarding and progressive place to build a career within the biotechnology and biopharmaceutical sector...
Nvidia Corporation possesses an exceptionally strong future growth outlook driven by its dominant market share in artificial intelligence computing, graphics processing units, and high-performance data center infrastructure.
Equity research analysts covering Li Auto, trading under the ticker symbol LI, maintain mixed consensus recommendations reflecting intense price competition in China's electric vehicle market.
Equity trading under the ticker symbol APLS reflects the corporate history and clinical development milestones of Apellis Pharmaceuticals, a commercial-stage biotechnology enterprise focused on complement immunotherapy.